Cargando…
Kidney Cancer Models for Pre-Clinical Drug Discovery: Challenges and Opportunities
Renal cell carcinoma (RCC) is among the most lethal urological malignancies once metastatic. The introduction of immune checkpoint inhibitors has revolutionized the therapeutic landscape of metastatic RCC, nevertheless, a significant proportion of patients will experience disease progression. Novel...
Autores principales: | Pohl, Laura, Friedhoff, Jana, Jurcic, Christina, Teroerde, Miriam, Schindler, Isabella, Strepi, Konstantina, Schneider, Felix, Kaczorowski, Adam, Hohenfellner, Markus, Duensing, Anette, Duensing, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128013/ https://www.ncbi.nlm.nih.gov/pubmed/35619925 http://dx.doi.org/10.3389/fonc.2022.889686 |
Ejemplares similares
-
BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study
por: Friedhoff, Jana, et al.
Publicado: (2022) -
Digital Spatial Profiling Identifies the Tumor Periphery as a Highly Active Biological Niche in Clear Cell Renal Cell Carcinoma
por: Schneider, Felix, et al.
Publicado: (2023) -
Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery
por: Li, Jielin, et al.
Publicado: (2021) -
Cullin 5 is a novel candidate tumor suppressor in renal cell carcinoma involved in the maintenance of genome stability
por: Tapia-Laliena, María Ángeles, et al.
Publicado: (2019) -
Bortezomib: killing two birds with one stone in gastrointestinal stromal tumors
por: Duensing, Stefan, et al.
Publicado: (2010)